Report: 2026 Patient Support Awards Name Leaders in Large, Small Pharma
Nuvera, an Inizio Engage brand, announced winners of its 2026 Best-in-Class Patient Support Program Awards, with AbbVie, Sanofi/Regeneron, Pfizer, and Genentech among the top large pharma companies across various therapeutic areas. Rankings are based on feedback from over 2,300 physicians and healthcare staff. Winners will be recognized at the Informa Patient Pathways Congress in November. Nuvera also noted the increasing role of AI in patient support programs.
How this was made
The 30-second read
Why it matters
The rankings provide reputational insight but lack direct financial implications.
Market read
The article offers a fresh ranking list; relevance to traders is minimal.
What to watch
Potential longer‑term brand equity benefits and future contract wins are not captured.
Background
Nuvera's PURE Engagement research ranks pharma companies on patient support programs based on physician and staff feedback.
Ticker impact
AbbVie ranked top in three large‑pharma categories in Nuvera's 2026 patient support awards.
likely little price movement as the award is not a financial catalyst.
The award is a new disclosure but does not affect earnings, contracts, or cash flow.
Sanofi tied with Regeneron for top spots in dermatology and respiratory categories.
unlikely to move the stock materially.
Award rankings are informational, not a catalyst for price change.
Regeneron shared top rankings with Sanofi in dermatology and respiratory categories.
no significant price effect expected.
Award results are new but not linked to earnings or contracts.
Pfizer tied for best‑in‑class oncology support program.
little to no price movement anticipated.
Award is a fresh fact but lacks material financial relevance.
Amgen placed second in oncology and rheumatology rankings.
unlikely to affect price.
Ranking information is new but not financially material.
Eli Lilly appeared behind Pfizer/Genentech in oncology ranking.
no meaningful price impact.
Award data does not alter financial outlook.
Johnson & Johnson placed second in rheumatology, dermatology, and gastroenterology.
unlikely to move the stock.
Award ranking is informational, not financially material.
AstraZeneca ranked second in respiratory after Sanofi/Regeneron.
no significant price change expected.
Award data is new but lacks material financial relevance.
Market effects
Shows competitive landscape in patient support programs but no immediate sector shift.
U.S. pharma reputation focus; no regional market move.
Limited global impact; awards are niche and reputational.
Counterpoint
Investors may view the awards as low‑impact and ignore them in valuation models.
Key entities
- CompanyNuvera
Provider of patient support program rankings.
- CompanyInizio Engage
Parent brand of Nuvera.
